Research funder · United States
Michael J. Fox Foundation for Parkinson's Research
Non-profit organization in the USA
- Grants since 2016
- 1 275
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 3 085
- Funded works, all time
- 6 716
Grants
2025 · research · Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers
An International Working Group for the Evaluation of Mitochondrial DNA as a PD Biomarker
Julia C. Fitzgerald · University of Tübingen
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Allosteric Small Molecule Therapies for Treating GBA1-PD
Indranath Ghosh · Congruence Therapeutics
2025 · research · T2T Validation - NOD2
Using Knowledge Graphs to Predict NOD2 Directionality for Therapeutic Effect in Parkinson’s Disease
Virginie Buggia-Prevot · Valo Health
2025 · research · 2021 RFA: Improved Outcome Measures
Volatile Biomarkers of Prodromal Parkinson’s Disease from Sebum
Marianna Cortese · Harvard University
2025 · research · Accelerating Biological Understanding and Therapeutic Translation for PD-Biology
Studying SCAMPs: Membrane Proteins that Control Trafficking of Alpha-synuclein
Randy Schekman · Aligning Science Across Parkinson's
2025 · research · Spring 2025 RFA: Molecular MRI Biomarker Program
Molecular Magnetic Resonance Imaging (mMRI) GlioScope: A Comprehensive Approach to Noninvasive Profiling of Neuroinflammation in Pre-clinical Models of Parkinson’s Disease.
Eric Tanifum · Baylor College of Medicine
2025 · research · Neuronal Synuclein Disease Endotypes 2024
Integrated Analysis of Alpha-synuclein in the North American Prodromal Synucleinopathy (NAPS) Cohort
Albert Augustus (Gus) Davis · Washington University in St. Louis
2025 · research · Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology
The Role of the Transcriptome in PD: A Novel Approach to PD Therapeutics
Laura Ibanez · Washington University in St. Louis
2025 · research · Neuronal Synuclein Disease Endotypes 2024
Identifying Biomarkers for the Common Mechanism Underlying the Disease Continuum from Parkinson’s Disease to Alzheimer’s Disease
Dag Aarsland · King's College London
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
(SUPPLEMENT) Discovery of Translational Biomarkers for Endolysosomal Pathway Pathology Using Lipidomics and Metabolomics
Joanna Wolak · Endlyz Uk Limited
2025 · research · Research Grant
Click Chemistry-based Alpha-synuclein PET Biomarker Discovery
Hartmuth C. Kolb · Enigma Biomedical Group
2025 · research · Research Grant
Phenotypic and Construct Validity of Pink1-/- in Pre-clinical Models for Pre-clinical Parkinson’s Research
Cynthia A. Kelm-Nelson · University of Wisconsin–Madison
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Neuro-steroid Mediated Control of Sleep Co-morbidities in Parkinson's Disease
Gilberto Fisone · Karolinska Institutet
2025 · research · Research Grant
Personalized Parkinson Project (PPP)
Bastiaan R. Bloem · Radboud University Medical Center
2025 · research · ASAP CRN Competitive Renewal Opportunity
Examining the Dual Role of Neural Activity in Parkinson’s Disease
Robert Edwards · University of California, San Francisco
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Assessing Pre-clinical Efficacy of Brain-penetrant TRPML1 Agonists to Treat Parkinson’s Disease
Valerie Cullen · Lysoway Therapeutics, Inc
2025 · research · Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers
Development of an Assay for Rapid Detection of Activated LRRK2
Ahmed Soliman · Brigham and Women's Hospital
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Pre-clinical Development of Novel GCase Variants for Treating Parkinson’s Disease
Gjalt W. Huisman · Embold Therapeutics, Inc.
2025 · research · Research Grant
Potent Inhibitors of Deubiquitinating Enzyme USP14 as Inducers of Parkin-independent Mitophagy
Daniel J. Finley · Harvard University
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Biomarker and IND-enabling Studies to Advance a CNS Penetrant GCase Activator for the Treatment of Parkinson’s Disease
Nicholas J. Brandon · Neumora Therapeutics
2025 · research · Freezing of Gait Program
AID-FOG: Artificial Intelligence-driven Freezing of Gait Detection in the Home
Moran Gilat · KU Leuven
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
SNP614, A LRRK2 Antisense Oligonucleotide as Potential Therapeutic Agent for Parkinson's Disease
Yuka Atagi Martens · Scineuro Therapeutics Inc.
2025 · research · Parkinson’s Disease Therapeutics Pipeline Program
Development of Selective CaV1.3 Inhibitors as a Disease-modifying Therapy for Parkinson’s Disease
Thomas Stephen Otis · Lario Therapeutics
2025 · research · Neuronal Synuclein Disease Endotypes 2024
Expanding Biomarker Characterization in Deeply Phenotyped DLB, PD and PDD Cohorts
Frank P. Difilippo · Cleveland Clinic Lerner College of Medicine
2025 · research · MRI Biomarkers Program
Evaluation of Neuromelanin-sensitive, Quantitative Susceptibility Mapping and Free Water Imaging as Biomarkers of Nigral Dopaminergic Dysfunction
Stephane Lehericy · Pitié-Salpêtrière Hospital
2025 · research · Research Grant
Developing an ELISA Immunoassay for Monitoring Phosphorylation of Proteins Associated with Parkinson’s Disease
Kyle Berg · Quansys Biosciences
2024 · research · Accelerating Biological Understanding and Therapeutic Translation for PD-Biology
Characterization of a Preclinical Model Bearing a Parkinson’s Disease–linked Mutation in PLA2G6
Miratul Muqit · University of Dundee
2024 · research · Parkinson’s Disease Therapeutics Pipeline Program
A Translational Investigation of Drugs that Modulate Circadian Rhythm in Models of Parkinson’s Disease
Sridhar Vasudevan · University of Oxford
2024 · research · Spring 2022 RFA: Therapeutic Pipeline Program Pre-Clinical
Exploring Paxalisib as a Novel Therapeutic for Parkinson’s Disease
Ronit Sharon · Hebrew University of Jerusalem
2024 · research · Research Grant
(SUPPLEMENT) Disparities in Neurocognitive Impairment among Hispanics/Latinos in the US with Parkinson’s Disease: The Role of Cardiovascular Risk
María J. Marquine · University of California San Diego
2024 · research · Parkinson’s Disease Therapeutics Pipeline Program
Biomarker Development and IND-Enabling Toxicology Support for Novel, Small Molecules that Enhance Lysosomal Function for the Treatment of Parkinson’s Disease
Martin B. Gill · Libra Therapeutics, Inc.
2024 · research · Parkinson’s Disease Therapeutics Pipeline Program
IND-enabling Studies of a Molecule that Enhances Mitophagy as Disease-modifying Therapy for Parkinson's Disease
Bahareh (Spring) Behrouz · Vincere Biosciences Inc
2024 · research · Parkinson’s Disease Therapeutics Pipeline Program
Use of the Dual-action Neuroprotective Compound KLS-13019 to Treat Motor Impairment in a Preclinical Model of Parkinson’s Disease
Douglas E. Brenneman · Kannalife Sciences
2024 · research · Research Grant
SUPPLEMENT: MJFF Consortium on PRKN and PINK1
Christine Klein · University Of Lubeck; University Hospital Of Schleswig-holstein
2024 · research · Alpha-synuclein Seed Amplification Assay Program
Maximizing Sensitivity of Alpha-synuclein Seed Amplification Assays by Eliminating Spontaneous Aggregation
Alexander Kai Buell · Technical University of Denmark
2024 · research · Parkinson’s Disease Therapeutics Pipeline Program
A Clinical Trial to Investigate the Safety of Repeated Subcutaneous Injections of HER-096, a Novel Candidate for Disease-modifying Therapy in Parkinson’s Disease
Henri J. Huttunen · Herantis Pharma Plc
2024 · research · Research Grant
Powered Clothing and Wearable Robotics for Everyday Gait Support
Anna Roumiantseva · Skip Innovations
2024 · research · Accelerating Biological Understanding and Therapeutic Translation for PD-Biology
Interrogating Novel Defects in Protein Glycosylation in GBA1-associated Parkinson’s Disease
Matthew J. Lavoie · University of Florida
2024 · research · Parkinson’s Disease Therapeutics Pipeline Program
Assessment of IRL757 for the Treatment of Apathy in Parkinson's Disease
Joakim Tedroff · Integrative Research Laboratories
2024 · research · Accelerating Biological Understanding and Therapeutic Translation for PD-Biology
Evaluating the Neuroprotective Factor REST as a Target for Parkinson’s Disease
Nora Bengoa-Vergniory · Achucarro Basque Center for Neuroscience